How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,034 results for

Type 2 Diabetes Mellitus in Children

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Type 2 diabetes in children

of children aged ≥10 years with type 2 diabetes. US Food and Drug Administration. FDA approves new treatment for pediatric patients with type 2 diabetes. Jun 2019 [internet publication]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-pediatric-patients-type-2-diabetes Liraglutide has been approved for use in adults since 2010, but the only approved treatment options available for younger children with type 2 diabetes were metformin or insulin. However, the TODAY study group (...) of liraglutide for reducing blood sugar in paediatric patients with type 2 diabetes was studied in one placebo-controlled trial with 134 patients aged ≥10 years for more than 26 weeks. Approximately 64% of patients in the study had a reduction in their haemoglobin A1c (HbA1c) below 7% while on liraglutide, compared with only 37% who achieved these results with the placebo. All the patients also received metformin during the trial. Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. Liraglutide in children

2019 BMJ Best Practice

3. Management of Type 2 Diabetes Mellitus

Management of Type 2 Diabetes Mellitus Quality Department Guidelines for Clinical Care Ambulatory Diabetes Mellitus Guideline Team Team Leaders Connie J Standiford, MD General Internal Medicine Sandeep Vijan, MD General Internal Medicine Team Members Hae Mi Choe, PharmD College of Pharmacy R Van Harrison, PhD Medical Education Caroline R Richardson, MD Family Medicine Jennifer A Wyckoff, MD Metabolism, Endocrinology & Diabetes Consultants Martha M Funnell, MS, RN, CDE Diabetes Research (...) proper methods of care or excluding other acceptable methods of care reasonably directed to obtaining the same results. The ultimate judgment regarding any specific clinical procedure or treatment must be made by the physician in light of the circumstances presented by the patient. Management of Type 2 Diabetes Mellitus Patient population. Adults Objectives. To reduce morbidity and mortality by improving adherence to important recommendations for preventing, detecting, and managing diabetic

2020 University of Michigan Health System

4. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Full Text available with Trip Pro

Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Intermediate hyperglycaemia (IH) is characterised by one or more measurements of elevated blood glucose concentrations, such as impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and elevated glycosylated haemoglobin A1c (HbA1c). These levels are higher than normal but below the diagnostic threshold for type 2 diabetes mellitus (T2DM). The reduced threshold of 5.6 mmol/L (100 mg/dL) fasting plasma (...) glucose (FPG) for defining IFG, introduced by the American Diabetes Association (ADA) in 2003, substantially increased the prevalence of IFG. Likewise, the lowering of the HbA1c threshold from 6.0% to 5.7% by the ADA in 2010 could potentially have significant medical, public health and socioeconomic impacts.To assess the overall prognosis of people with IH for developing T2DM, regression from IH to normoglycaemia and the difference in T2DM incidence in people with IH versus people

2018 Cochrane

5. Type 2 diabetes in children

Type 2 diabetes in children Type 2 diabetes in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Type 2 diabetes in children Last reviewed: February 2019 Last updated: March 2019 Summary A progressive disorder due to a deficit in both insulin secretion and insulin action, with obesity being the primary cause in children. Often asymptomatic and diagnosed by screening in a high-risk individual (e.g., family (...) ). Treatment includes lifestyle modifications, metformin, and insulin. Definition Type 2 diabetes mellitus is a progressive disorder due to a deficit in both insulin secretion and insulin action leading to abnormal glucose metabolism and related metabolic derangements. Diagnosis is based on a fasting plasma glucose of 7 mmol/L or greater (126 mg/dL or greater) on 2 separate occasions, a random plasma glucose of 11.1 mmol/L or greater (200 mg/dL or greater) with symptoms of polyuria or polydipsia, a plasma

2018 BMJ Best Practice

6. Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid (Steglatro) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86938/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report (...) the Fridericia formula R AC Accumulation ratio RH relative humidity RQ (Environmental) Risk Quotient SBP systolic blood pressure SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics TAMC total aerobic microbial count TYMC total combined yeasts/moulds count T2DM type 2 diabetes mellitus t max time to C max UGE urinary glucose excretion UGT uridine 5’-diphospho-glucuronosyltransferase ULN upper limit of normal UV ultraviolet UV-Vis ultraviolet

2018 European Medicines Agency - EPARs

7. Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / sitagliptin phosphate monohydrate (Steglujan) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86941/2018 Committee for Medicinal Products (...) in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control - when metformin and/or a sulphonylurea (SU) do not provide adequate glycaemic control. - when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control. - in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets. (See sections 4.2, 4.4, 4.5, and 5.1 for available

2018 European Medicines Agency - EPARs

8. Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2

Ertugliflozin l-pyroglutamic acid / metformin hydrochloride (Segluromet) - Diabetes Mellitus, Type 2 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 25 January 2018 EMA/86928/2018 Committee for Medicinal Products for Human Use (...) analysis plan SGLT1 sodium-glucose co-transporter 1 SGLT2 sodium-glucose co-transporter 2 SmPC summary of product characteristics SMQ Standard MedDRA Query SOC System organ class T2DM type 2 diabetes mellitus TAMC total aerobic microbial count Tmax time to first occurrence of maximum observed concentration TYMC total combined yeasts/moulds count UGE urinary glucose excretion ULN upper limit of normal US United States USPI United States Prescribing Information UTI urinary tract infection UV ultraviolet

2018 European Medicines Agency - EPARs

9. The Management of Insulin Administration and Blood Glucose Monitoring in Children with Type 1 Diabetes Mellitus: Guidelines

were identified regarding the management of insulin administration and the monitoring of blood glucose in children with Type 1 diabetes mellitus. Tags pediatrics, adolescent, blood glucose, child, diabetes mellitus, type 1, insulin, schools, blood sugar, daycare, preschool, student, Administer, Monitoring Files Rapid Response Summary of Abstracts Published : May 24, 2017 Related Content Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) The Management of Insulin Administration and Blood Glucose Monitoring in Children with Type 1 Diabetes Mellitus: Guidelines The Management of Insulin Administration and Blood Glucose Monitoring in Children with Type 1 Diabetes Mellitus: Guidelines | CADTH.ca Find the information you need The Management of Insulin Administration and Blood Glucose Monitoring in Children with Type 1 Diabetes Mellitus: Guidelines The Management of Insulin Administration and Blood Glucose Monitoring in Children

2017 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

million adults in the United States have type 2 diabetes mellitus (DM), whereas 6.5 million have heart failure (HF), and both conditions are expected to continue to increase in prevalence over time. Although DM and HF are each individually associated with considerable morbidity and mortality, they often occur together, which further worsens adverse patient outcomes, quality of life, and costs of care. Identifying and implementing optimal treatment strategies for patients living with DM and HF (...) -1 receptor agonists if no recent HF decompensation) could be considered, but use with caution; may require dose adjustment DM indicates diabetes mellitus; DPP-4, dipeptidyl peptidase-4; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT-2, sodium glucose cotransporter type 2; and TZDs, thiazolidinedione drugs. Figure 3

2019 American Heart Association

11. Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules)

Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years (Sick Day Rules) 1 Version 4, Feb 2018 Review 2021 Authors: SM Ng, A Soni, JC Agwu, JA Edge, JH Drew, C Moudiotis, NP Wright, M Kershaw, MC Gardner, L Connellan, W Assam ssociation of Children’s Diabetes Clinicians Clinicians SETTING FOR STAFF Medical and nursing staff PATIENTS Children and young people with diabetes mellitus Contents 1. Introduction 2 2. Importance of Local ‘Sick-Day’ Rules 2 3 (...) . Ketone testing 2 4. Fluid Management 3 5. Out of hours diabetes advice 4 6. Diabetes Self Management Education 4 7. General Rules for Managing Diabetes During Illness 4 7.1. Using sick day doses on pump therapy 7 7.2. Management of infections usually associated with hypoglycaemia eg. gastroenteritis ... 7 8. References 8 9. Appendix: Patient Advice Leaflet…………………………………………………………………...10 Clinical Guideline Management of Type 1 Diabetes Mellitus during illness in children and young people under 18 years

2019 British Society for Paediatric Endocrinology and Diabetes

12. Diabetes (type 1 and type 2) in children and young people: diagnosis and management

://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 12 of 85diagnosis and classification of diabetes mellitus. [2004, amended 2015] [2004, amended 2015] 1.1.4 When diagnosing diabetes in a child or young person, assume type 1 diabetes unless there are strong indications of type 2 diabetes, monogenic or mitochondrial diabetes (see recommendations 1.1.5 and 1.1.6). [new 2015] [new 2015] 1.1.5 Think about the possibility of type 2 diabetes in children and young people with suspected diabetes who: have (...) is a long-term condition that can have a major impact on the life of a child or young person, as well as their family or carers. In addition to insulin therapy, diabetes management should include education, support and access to psychological services, as detailed in this guideline. Preparations should also be made for the transition from paediatric to adult services, which have a somewhat different model of care and evidence base. Type 1 diabetes is becoming more common in the UK, and since 2004 type 2

2015 National Institute for Health and Clinical Excellence - Clinical Guidelines

13. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar)

) trial. The European Medicines Agency (EMA) has approved Abasaglar for treatment of diabetes mellitus in adults, young people and children aged 2 years and above. There are no published clinical studies comparing Abasaglar with Lantus in children and young people. However, the summary of product characteristics includes reference to paediatric studies with Lantus. Context Alternativ Alternative treatments e treatments Basal insulin supply for people with type 1 or type 2 diabetes can be provided (...) significantly different between Abasaglar and Lantus in either study. As would be expected the total incidence of hypoglycaemic episodes was greater in people with type 1 diabetes than in people with type 2 diabetes, where 60% of participants were insulin naive at entry into the study. There are no published clinical studies comparing Abasaglar with Lantus in children and young people. However, the summary of product characteristics includes reference to paediatric studies with Lantus. Medication errors

2015 National Institute for Health and Clinical Excellence - Advice

14. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians Full Text available with Trip Pro

Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians ACP Guidance Statement on HbA | Annals of Internal Medicine | American College of Physicians '); } Sign in below to access your subscription for full content INDIVIDUAL SIGN IN | You will be directed to acponline.org to register and create your Annals account INSTITUTIONAL SIGN IN | | Subscribe to Annals (...) of Internal Medicine . You will be directed to acponline.org to complete your purchase. Search Clinical Guidelines | 17 April 2018 Hemoglobin A 1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians Free Amir Qaseem, MD, PhD, MHA; Timothy J. Wilt, MD, MPH; Devan Kansagara, MD, MCR; Carrie Horwitch, MD, MPH; Michael J. Barry, MD; Mary Ann Forciea, MD; for the Clinical Guidelines

2018 American College of Physicians

15. Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus

The Ministry of Health's Drug Advisory Committee has recommended: Insulin glargine biosimilar (Basaglar) injection 100 units/ml cartridge for the treatment of type 1 and type 2 diabetes mellitus in adults, adolescents and children aged 6 years or above, where treatment with insulin is required. Subsidy status Insulin glargine biosimilar (Basaglar) injection 100 units/ml cartridge is recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indication. The manufacturer has offered (...) Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus '); } else { document.write(' '); } ACE | Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Search > > Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus - Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus Published on 16 October 2017 Guidance Recommendation

2017 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

16. A Practical Approach to the Management of Continuous Glucose Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years

FOR STAFF Healthcare professionals involved in care of children and young people with Type 1 Diabetes Mellitus PATIENTS Children and young people with diabetes mellitus This guideline is intended for use in managing continuous glucose monitoring (CGM) or real-time flash glucose scanning (FGS) for all children and young people under 18 years with Type 1 diabetes mellitus. Table of Contents Introduction 2 Overview of Pertinent NICE guidance 3 Devices Available for CGM and FGS 6 Section 1: Evidence (...) Monitoring (CGM) / Real-Time Flash Glucose Scanning (FGS) in Type 1 Diabetes Mellitus in Children and Young People Under 18 years 2 Version 3, Oct 2018 Review 2021 Authors: ACDC Guideline Development Group N Wright, SM Ng, JC Agwu, P Adolfsson, J Drew, J Pemberton, M Kershaw, S Bissell, C Moudiotis, F Regan, C Gardner, A Astle, A Adams, G Adams, P Manning, A Timmis, A Soni, E Williams ssociation of Children ’s Diabetes Clinicians Introduction Real-time continuous glucose monitoring (CGM) and flash

2018 British Society for Paediatric Endocrinology and Diabetes

17. The Effect of Sleep Hygiene Education on Sleep Quality in Children with Type 1 Diabetes Mellitus: A Preliminary Study. (Abstract)

The Effect of Sleep Hygiene Education on Sleep Quality in Children with Type 1 Diabetes Mellitus: A Preliminary Study. To identify the effect of sleep hygiene education on sleep quality in children with Type 1 Diabetes Mellitus (T1DM), a quasi-experiment with control group and pretest-posttest design was conducted. Samples of 46 children with T1DM in IKADAR were assigned into intervention (n = 23) and control (n = 23). The intervention group received sleep hygiene education for 10 minutes via (...) hygiene can improve sleep quality in children with T1DM; therefore, it can be implemented as a nursing intervention to overcome sleep disorder in children with T1DM.

2019 Comprehensive child and adolescent nursing Controlled trial quality: uncertain

18. Use of the microbiome in the management of children with type 2 diabetes mellitus. (Abstract)

Use of the microbiome in the management of children with type 2 diabetes mellitus. The purpose of this review is to present recent data that defines our current understanding of the role of the gut microbiome in the development of T2DM.Recent studies focus on the physiology and molecular pathways of the gut microbiome-host interaction. Short-chain fatty acids (SCFAs) derived from the fermentation of plant-based nonsoluble fiber bind to G-protein-coupled receptors (GPR) GPR 41 and GPR 43 (...) inflammation, insulin resistance and type II diabetes mellitus.Recent scientific data support that derangements in the composition of the microbiota, termed "microbiome dysbiosis" is a factor in the development of "metabolic endotoxemia" and T2DM. Therapeutic options that target the gut microbiome in the treatment of T2DM are explored.

2019 Current opinion in pediatrics

19. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care.

and Department of Defense (VA and DoD) healthcare delivery systems, which includes Veterans, deployed and non-deployed Active Duty Service Members, and their adult family Refer to the original guideline document for specific populations for key questions. Note : This clinical practice guideline (CPG) does not provide recommendations for the management of DM in children, adolescents, or pregnant/nursing women. General approach to type 2 diabetes mellitus care Shared decision-making Individualized diabetes (...) VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. VA/DoD clinical practice guideline for the management of type 2 diabetes mellitus in primary care. | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 03 Oct 2017 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted

2017 National Guideline Clearinghouse (partial archive)

20. Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above

Insulin glargine (Abasaglar) - for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above Final Appraisal Recommendation Advice No: 3715 – November 2015 Tinzaparin sodium (innohep ® Syringe) 20,000 units/ml solution for injection Limited submission by LEO Pharma Additional note(s): • This advice may be considered in conjunction with AWMSG recommendations on the prescribing of low molecular weight heparin in Wales. In reaching the above recommendation AWMSG

2015 All Wales Medicines Strategy Group

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>